News Release

HIV reservoirs remain obstacles to cure

NIH scientists note need for better understanding of reservoirs' biology

Peer-Reviewed Publication

NIH/National Institute of Allergy and Infectious Diseases

WHAT:

Antiretroviral therapy (ART) has proven lifesaving for people infected with HIV; however, the medications are a lifelong necessity for most HIV-infected individuals and present practical, logistical, economic and health-related challenges. A primary research goal is to find an HIV cure that either clears the virus from an infected person's body or enables HIV-infected individuals to suppress virus levels and replication to extremely low levels without the need for daily ART.

In a new perspective article, National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony S. Fauci, M.D., and colleagues describe how persistent HIV reservoirs form in the human body and why they pose formidable challenges to achieving a cure. Additionally, the authors discuss the current therapeutic research strategies aimed at eliminating or controlling the virus without daily ART, including making CD4+ T cells resistant to HIV and enhancing host immunity against infection. A better understanding of persistent viral reservoirs and the impact of therapeutic interventions on these reservoirs is essential to the development of successful therapeutic strategies aimed at the long-term control of HIV infection, according to the authors.

While recent scientific advances and increased funding aimed at developing therapeutic strategies toward an HIV cure have yielded valuable insights into the pathogenesis of HIV-related disease, achieving an HIV cure remains extremely challenging, the authors note. However, recent advances give cause for hope. Attaining a cure will require strong and sustained efforts to better understand the establishment, composition, maintenance, and renewal of HIV reservoirs, according to the authors.

###

ARTICLE:

T-W Chun, S Moir, and AS Fauci. HIV Reservoirs: Obstacles and Opportunities for an HIV Cure. Nature Immunology DOI: 10.1038/ni.3152 (2015).

WHO:

Anthony S. Fauci, M.D, NIAID director, is available for comment.

CONTACT:

To schedule interviews, please contact Robin Tricoles, (301) 402-1663, robin.tricoles@nih.gov.

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.